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ABSTRACT
Background: Novel and new therapeutic strategies capable of enhancing the efficacy of
existing antimicrobials is an attractive proposition to meet the needs of society.
Objective: This study aimed to evaluate the potentiating effect of a miconazole (MCZ)
nanocarrier system, incorporated with iron oxide nanoparticles (IONPs) and chitosan (CS)
(IONPs-CS-MCZ). This was tested on three representative complex interkingdom oral biofilm
models (caries, denture and gingivitis).
Materials and methods: The planktonic and sessile minimum inhibitory concentrations (MICs)
of IONPs-CS-MCZ against different Candida albicans strains were determined, as well as against
all represented bacterial species that formed within the three biofilm models. Biofilms were
treated for 24 hours with the IONPs-CS nanocarrier system containing MCZ at 64 mg/L, and
characterized using a range of bioassays for quantitative and qualitative assessment.
Results: MIC results generally showed that IONPs-CS-MCZ was more effective than MCZ alone.
IONPs-CS-MCZ also promoted reductions in the number of CFUs, biomass and metabolic
activity of the representative biofilms, as well as altering biofilm ultrastructure when compared
to untreated biofilms. IONPs-CS-MCZ affected the composition and reduced the CFEs for most
of the microorganisms present in the three evaluated biofilms. In particular, the proportion of
streptococci in the biofilm composition were reduced in all three models, whilst Fusobacterium
spp. percentage reduced in the gingivitis and caries models, respectively.
Conclusion: In conclusion, the IONPs-CS-MCZ nanocarrier was efficient against three in vitro
models of pathogenic oral biofilms, showing potential to possibly interfere in the synergistic
interactions among fungal and bacterial cells within polymicrobial consortia.
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Introduction
Oral diseases are globally prevalent, and themisdiagnosis
or non-treatment of such diseases can result in systemic
complications. Gingivitis for example is considered by
many a common and easy to treat oral inflammatory
disease, but when left untreated can lead to destructive
periodontitis, a disease that affects 10% of global popula-
tion [1]. According to World Health Organization
(WHO) surveys, dental caries is the most common dis-
ease in humans, affecting 49 to 83.4% of children [1].
Similarly, the prevalence of denture stomatitis has also
been increasing in elderly people and denture wearers, as
well as immunocompromised patients, and with a drive
to maintain natural dentition we have seen a rise in
partial dentures in younger adult patients [2–4]. These
biofilm-mediated diseases can all be easily prevented
with effective self-directed oral hygiene measures (bio-
film disruption and chemical disinfection), yet unneces-
sary risk related to human behavior frequently leads to
oral disease requiring antimicrobial intervention. For
effective treatment and/or control of different oral bio-
films, this requires a tacit understanding of the nature of
the causative oral microbiome in order to recapitulate
these interactions in vitro. Existing biofilm models often
fail to account for polymicrobiality, a characteristic asso-
ciated with the pathogenesis of gingivitis, caries and
denture stomatitis [5,6]. Instead, commercial models
for drug discovery rely on simplified mono-species bio-
films that provide an inferior challenge to antimicrobial
therapies. Importantly, and frequently, C andidaalbicans
participates in inter-kingdom interactions as an oppor-
tunistic fungus whose association with different bacteria
favours synergized tolerance to conventional treatment
[7–10]. This yeast is capable of reducing the oxygen
tension in the biofilm and providing growth stimulatory
factors that allows a synergistic relationshipwith bacteria,
also supporting the growth of early and later colonizers
of oral biofilms [6,8]. C. albicans can also physically
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interact with a number of oral bacterial species such as
oral streptococci, Fusobacterium nucleatum and
Porphyromonas gingivalis through well-characterized
physical surface protein receptor interactions between
bacterial and fungal cells [7,11,12]. As the number of
studies on C. albicans increases, its physical and meta-
bolic role within the oral microbiome, and inter-depen-
dencies, are beginning to be better understood. Thus,
in vitro models investigating the development of novel
antimicrobial therapies warrant the use of polymicrobial
interkingdom biofilms containing fungal and bacterial
species to more accurately assess new and novel antimi-
crobial strategies.
In this current era of antimicrobial resistance, inno-
vating treatments and the discovery and administration
of novel antimicrobials is becoming increasingly pro-
blematic. The constant exposure of microorganisms to
these antimicrobials, even at low levels, can lead to
mutations and new resistance mechanisms [13].
Azoles are considered a major problem in this sense,
with oral candidiasis including denture stomatitis fre-
quently treated with azole antifungals [14]. In addition,
use of broad spectrum antibiotics including azoles such
as metronidazole have been reported for treatment of
periodontal lesions resulting from mixed bacterial and
fungal infections [15]. Miconazole (MCZ) has also pro-
ven to be a good antimicrobial choice since its broad-
spectrum activity effects against both fungi and differ-
ent bacteria species [16]. Such activity is clinically desir-
able for a polymicrobial clinical challenge, but clinical
and laboratory-based reports of microbial resistance
and azole cross resistance alert us to the risk of over-
reliance on these treatments [10,17–19]. Thus, alterna-
tive strategies such as the use of drug nanocarriers
which enhance the action of conventional drugs by
facilitating their delivery to target cells and overcoming
the biofilm physical barriers warrant further considera-
tion. These systems aim to reduce the concentration of
drug required, exposure time and increase the efficacy
of the drug against the microorganisms [20,21]. To this
end, iron oxide magnetic nanoparticles (IONPs) have
recently been studied for different clinical applications,
including hyperthermia, magnetic resonance imaging,
tissue repair and drug delivery [21]. More recently,
in vitro studies have described IONP-based nanosys-
tems that possess anti-biofilm purposes, whose nano-
and magnetic properties promise to meet the optimiza-
tion needs of antimicrobial treatments, interfering with
the composition of pathogenic biofilms [22,23].
Therefore, the aim of the present study was to investi-
gate the effect of a recently developedMCZ nanocarrier
based on IONPs and chitosan (CS) [24], on the compo-
sition of three in vitro biofilm models representative of
pathogenic interkingdom oral biofilms. This is the first
study to show that a nanosystem based on IONPs and
CS can efficiently carry miconazole and are effective
against pathogenic oral polymicrobial interkingdom
biofilms in vitro.
Materials and methods
All biofilm work for this study and preparation of the
manuscript was carried out in accordance with the
minimum information guidelines specified for bio-
film formation in microplates [25].
Assembly and characterization of the IONPs-CS-
MCZ nanocarrier
A stock solution of the nanocarrier was prepared by the
mixture of equal volumes of a IONPs colloidal suspension
(700 mg/L) and CS (700 mg/L) followed by the MCZ
solubilization (500 mg/L) into the core-shell compound
IONPs-CS, as previously described for a chlorhexidine-
carrier nanosystem [22]. As before, the colloidal suspen-
sion of IONPswas kindly provided by nChemi (Sao Paulo,
Brazil). Development of this novel IONPs-CS-MCZ sys-
tem is detailed elsewhere [24].
Strains and growth conditions
Twelve strains of C. albicans were utilized in the current
study, including 10 clinical oral isolates (BC020, BC023,
BC037, BC038, BC039, BC117, BC136, BC145, BC044,
BC146) from the Oral Sciences Research Group,
University of Glasgow, Glasgow, UK, and a key laboratory
reference strain (ATCC 10,231). Stock cultures stored in
MicrobankTM beads (Pro-lab Diagnostics, UK) at −80°C
were revived on Sabouraud dextrose agar (SAB agar). For
theMIC and biofilm assays, a loopful ofCandida colonies
was suspended in 10 mL of Yeast Extract Peptone
Dextrose (YPD) medium using a disposable 10 µL inocu-
lating loop (Thermo-Fisher, UK). Broths were cultured
aerobically overnight at 30°C, constantly shaken at
120 rpm. Following centrifugation, the fungal pellet was
washed twice in phosphate buffered saline (PBS) then the
suspension adjusted with the aid of a haemocytometer to
2 × 104 cells/mL, 1 × 106 cells/mL and 1 × 107 cells/mL for
planktonic, mono-culture, and polymicrobial biofilm eva-
luations, respectively.
For the multi-species biofilm models, the following
bacterial strains stored on MicrobankTM beads at −80°C
were used: Streptococcus mitis NCTC 12,261,
Streptococcus oralis NCTC 11,427, Streptococcus interme-
dius DSM 20,573, Streptococcus mutans NCTC 10,449,
Veillonella dispar NCTC 11,831, Actinomyces naeslundii
DSM 17,233, Lactobacillus casei DSMZ 20,011,
Lactobacillus zeae DSM 20,178, Rothia dentocariosa
DSM 43,762, Fusobacterium nucleatum ATCC 10,953
and Fusobacterium nucleatum vincentii DSM 19,507.
Streptococcus and Rothia species were revived on
Columbia Blood Agar base containing 10% defibrinated
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horse blood (CBA; Sigma–Aldrich, UK) overnight in 5%
CO2. Strict and facultative anaerobic strains (V. dispar,
A. naeslundii, F. nucleatum, F. nucleatum vicentii) were
cultivated on Fastidious Anaerobe Agar base containing
10% defibrinated horse blood (FAA; Sigma–Aldrich, UK)
in an anaerobic incubator (Don Whitley Scientific
Limited, UK) for 2–3 days, while Lactobacillus strains
were propagated on De Man Rogosa Sharpe Agar (MRS
agar; Sigma–Aldrich, UK) overnight in 5% CO2. The
temperature of incubation for all aforementioned bacterial
strains was 37°C. Following growth on solid agar,
a loopful from each bacterial strain was suspended in
10 mL of specific media (Tryptic Soy Broth (TSB;
Sigma–Aldrich, UK) for Streptococcus species, Brain
Heart Infusion broth (BHI; Difco, UK) for A. naeslundii,
V. dispar and R. dentocariosa, Schaedler’s anaerobic broth
(SCH; Oxoid, UK) for Fusobacterium and MRS broth for
Lactobacillus species) and incubated overnight at 37°C.
After the incubation period, the bacterial cells were
washed twice in PBS then concentration was adjusted to
1 × 108 cells/mL using a spectrophotometer. Absorbance
readings at A550 nm that equate to 1 × 10
8 cells/mL were
determined using serial dilutions of pure cultures and
Miles and Misra colony counting technique [26].
Determination of the MICs
MIC testing was employed to determine the MCZ
and IONPs-CS-MCZ MICs for planktonic (pMIC)
and sessile (sMIC) cells of the studied fungal and
bacterial strains. Briefly, for planktonic cells, 100 µL
of standardized cell suspensions (2 x 104 cells/mL for
Candida and 2 × 105 cells/mL for bacterial cells) in
the appropriate media for each microorganism
described above were pipetted in clear bottom
round-bottom wells of 96-well plates (Corning, UK)
containing 100 µL of a 2-fold serial dilution of MCZ
and IONPs-CS-MCZ with concentration ranging
from 0.5–256 mg/L, and the pMIC values were
visually determined after 24–48 hours. For this, the
lowest concentration to visually prevent growth of the
microorganisms was deemed the pMIC.
To determine the sMIC, 200 µL of the microbial
inoculum (1 x 106 cells/mL for fungal cells and 1 × 107
for bacterial cells) were pipetted in flat-bottom wells of
96-well clear bottom plates (Corning, UK) and biofilm
allowed to form for 24 hours at 37°C. The biofilms were
treated with 2-fold serial dilutions of MCZ and IONPs-
CS-MCZ ranging from 0.5–256 mg/L and incubated at
37°C under specific aerobic or anaerobic conditions
dependent on microbial species. After 24 hours, the
resulting biofilms were gently washed with PBS prior to
the addition of 100 µL of XTT [2,3-bis(2-methoxy-
4-nitro-5-sulfophenyl)-2 H-tetrazolium-5-carboxanilide
salt] (Sigma Aldrich, UK). After 2 hours of incubation
at 37°C, the absorbance values were read at 490 nm and
the sMIC50 and sMIC80 were considered the concentra-
tions that lead respectively to 50% and 80% reduction of
XTT readings, when compared to the untreated positive
control. All MIC tests were carried out on two separate
occasions in quadruplicate wells of a 96-well plate. For all
experiments, appropriate controls were included as fol-
lows; positive controls minus antimicrobial intervention
and negative controls minus inoculum were included on
each plate in quadruplicate.
Multi-species biofilm models and treatment
To assess the effect of IONPs-CS-MCZ on pathogenic
biofilms, three different in vitro multi-species biofilm
models were tested, representative of caries, denture
and gingivitis developed as previously described
[4,27,28]. For all biofilm models, the bacterial and
fungal cells were adjusted to 1 × 107 cells/mL in
Todd Hewitt Broth (THB) medium supplemented
with 0.01 mg/mL hemin and 2 µg/mL menadione
[29]. Biofilms were formed directly on the bottom
of wells of 24-well plates (Corning, UK) for XTT
reduction and biomass quantification assays, or on
13 mm Thermanox coverslips (Thermo-Fisher, UK)
placed in 24-well plates for CFU counting, qPCR
assays and SEM analysis.
Biofilm development for all models used followed
similar protocols as described previously [4,27,28,30].
Briefly, biofilm formation consisted of inoculating
Streptococcus species and C. albicans(500 µL) on the
first day to promote primary colonization, followed by
the addition of the remaining species on the second day.
In brief, for the gingivitis model, C. albicans, S. mitis,
S. oralis and S. intermedius were added on day 1 and
V. dispar, A. naeslundii, F. nucleatum and F. nucleatum
vicentii were added on day 2. For the denture model,
C. albicans, S. mitis, S. oralis and S. intermedius were
added on day 1 and V. dispar, A. naeslundii, L. casei,
L. zeae and R. dentocariosa were added on day 2.
Finally, for dental caries model, C. albicans and
S. mutans were added on day 1 and V. dispar,
A. naeslundii, F. nucleatum and L. casei were added
on day 2. All biofilms were then matured anaerobically
for an additional 4 days, and the culture media was
replenished every 24 hours. Afterwards, the stock solu-
tion of the IONPs-CS-MCZ nanocarrier was diluted in
THB supplemented media to the concentration of
64mg/mL ofMCZ, which was used to treat the biofilms
for 24 hours. Biofilms were also treated with MCZ only
at the same concentration, minus nanocarrier delivery.
Biofilms minus treatment (containingmedia only) were
considered as controls.
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Semi-quantitative biofilm analyses
After the treatment period, the biofilms were gently
washed three times with PBS then incubated with
250 µL of XTT. The plates were then protected
from light and incubated for 2 hours at 37°C. Next,
100 µL of each well’s content was transferred to 96-
well plates and the absorbance read at 490 nm to
determine the biofilms’ metabolic activity. To quan-
tify biofilm biomass, the crystal violet method was
applied, as described elsewhere [10]. Briefly, biofilms
received 250 µL of 0.05% w/v crystal violet for 20 min-
utes. Then, the remaining dye was removed, and the
biofilms were washed with water to remove any
excess dye. The microtiter plates were dried at room
temperature and biofilms de-stained with 99% etha-
nol. Finally, 100 µL of each wells’ content were trans-
ferred to 96-well microtiter plates and the results
were read at 570 nm. For all XTT and CV assays on
polymicrobial biofilms, experiments were done on
three independent occasions in triplicate in 24-well
plates. Appropriate controls minus microbial inocu-
lum were included on each plate in triplicate.
To analyze the biofilms ultrastructure after exposure
to MCZ only or the IONPs-CS-MCZ nanocarrier, the
biofilms were prepared for SEM analysis as reported
previously [31]. Briefly, the resulting biofilms were
washed with PBS and fixed in a solution containing
2% glutaraldehyde, 2% paraformaldehyde, 0.15% alcian
blue and 0.15 M sodium cacodylate (pH 7.4), and
further processed for SEM analysis. The samples were
sputter-coated with gold and viewed under a JEOL
JSM-6400 scanning electron microscope (JEOL Ltd,
UK) at a magnification of 1,000 x and 3,500 x,
respectively.
Quantitative biofilm analyses
Following treatment, the coverslips containing bio-
films were gently washed three times with PBS,
removed from the wells and transferred into bijoux
tubes containing 1 mL of PBS for sonication at
35 kHz for 10 min [30,32] to facilitate the disaggrega-
tion of biofilm cells. For CFU counting, the Miles and
Misra technique was employed [26]. Serial dilutions
were made in PBS then plated on specific agar media
(SAB for Candida, and CBA and FAA supplemented
with 0.025 mg/mL of Amphotericin B for aerobic and
anaerobic growth respectively). The CFUs were
counted after 48 hours incubation at 37°C for CBA
and FAA plates, and 30°C for 48 h for SAB plates.
A qPCR viability method was used to count the
microbial cells and determine the composition of the
biofilm models, as previously described [4,30]. In
short, the sonicated samples from above were split
into 2 Eppendorf tubes. For each group, one of the
Eppendorfs received 50 µM of propidium monoazide
(PMA; Sigma-Aldrich, UK) to quantify the viable
cells, prior to incubation of all samples in the dark
for 10 minutes to allow uptake and intercalation of
the PMA dye in double stranded DNA (dsDNA) of
compromised cells. Next, both sets of samples were
exposed to 650 W halogen light for 5 min; this
exposure to visible light initiates a covalent linkage
to form in the dsDNA inhibiting DNA amplification,
allowing for clear quantification of dead and viable
cells via real-time quantitative polymerase chain reac-
tion (qPCR). The DNA was then extracted from the
samples by using the QIAmp mini DNA Extraction
Kit (Qiagen, UK), according to the manufacturer’s
recommendations, and qPCR was employed to quan-
tify the viable cells of the biofilms. For qPCR,1 µL of
sample DNA was added to a mastermix solution
containing 10 µL of SYBR GreenERTM (Thermo-
Fisher, UK), 7 µL of UV-treated RNase-free water
and 1 µL of 10 µM forward/reverse primers for each
microbial genus or species. Table 1 displays the pri-
mers used in the study [4,27,28]. A total volume of
20 μl was added to MicroAmp fast-optical 96-well
0.1 ml reaction plates (Applied Biosystems, USA)
and loaded into the StepOnePlus™ real time system
(Applied Biosystems, USA). The following thermal
cycle was used: 95°C for 2 minutes, 40 amplification
cycles of 95°C for 3 seconds followed by 55°C for
Table 1. Bacterial and fungal primer sequences for real time PCR.
Target Primer sequence (5ʹ – 3ʹ) Reference
C. albicans F – GGGTTTGCTTGAAAGACGGTA [30]
R – TTGAAGATATACGTGGTGGACGTTA
Streptococcus spp. F – GATACATAGCCGACCTGAG [30]
R – CCATTGCCGAAGATTCC
A. naeslundii F – GGCTGCGATACCGTGAGG [30]
R – TCTGCGATTACTAGCGACTCC
V. dispar F – CCGTGATGGGATGGAAACTGC [30]
R – CCTTCGCCACTGGTGTTCTTC
Fusobacterium spp. F – GGATTTATTGGGCGTAAAGC [30]
R – GGCATTCCTACAAATATCTACGAA
L. casei F – TGCACTGAGATTCGACTTAA [27]
R – CCCACTGCTGCCTCCCGTAGGAGT
L. zeae F – TGCATCGTGATTCAACTTAA [4]
R – CCCACTGCTGCCTCCCGTAGGAGT
R. dentocariosa F – GGGTTGTAAACCTCTGTTAGCATC [4]
R – CGTACCCACTGCAAAACCAG
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30 seconds. All samples were run in duplicate.
Colony forming equivalents (CFEs) were quantified
using a standard curve of bacterial and fungal CFUs
ranging from 1 × 103 to 108 CFU/mL. For CFU
counts and qPCR analyses, experiments were com-
pleted in triplicate on two independent occasions.
Appropriate controls minus inoculum were included
for each experiment to assess for microbial contam-
ination of the media.
Statistical analysis
All microbiological assays were performed in tripli-
cate on at least two independent occasions. All graphs
were compiled and where appropriate, normally dis-
tributed data analysed by one-way ANOVA with
Tukey’s post-hoc to compare the means of more
than two group. A significance level was determined
at 5%, using the statistical program GraphPad Prism
(version 7; La Jolla, CA, USA).
Results
Determination of the MICs of Candida and
bacterial strains
The results of pMICs for all C. albicans strains revealed
the same susceptibility pattern to MCZ and IONPs-CS-
MCZ, with values ranging from 2 to 4 mg/L (Table 2).
For sMIC results, it was possible to observe lower MIC
values for the biofilms in response to the nanocarrier
compared to the MCZ, for both sMIC50 and sMIC80,
respectively. The analysis of susceptibility of oral strains
to MCZ showed that concentrations of 16 to 128 mg/L
(sMIC80) were required to reduce the metabolism of the
biofilms (Table 2). As for the nanocarrier, lower con-
centrations were required for all oral C. albicans strains
assessed under the same conditions (sMIC80). The con-
centrations of MCZ required in the nanosystem ranged
from 0.25 to 16 mg/L for all strains. A similar pattern
was observed for the reference strain of C. albicans
(ATCC 10,231), in which sMIC80 was 64 mg/L for
MCZ but 32 mg/L for MCZ in the IONPs-CS-MCZ
system (Table 2).
Table 3 shows the MIC values of the C. albicans and
bacterial strains included in the three studied biofilm
models (gingivitis, denture and dental caries). For all
bacterial species, MCZ and IONPs-CS-MCZ displayed
the same pMIC values, except for R. dentocariosa, for
which the nanocarrier showed lower values than MCZ
alone (>128mg/L forMCZ only, compared to 8mg/L for
the MCZ in the nanocarrier system). Regarding sMIC50,
IONPs-CS-MCZ showed similar or slightly lower values
compared to MCZ, except for A. naeslundii, whose
sMIC50 value for the nanocarrier was 4 times higher
than that found for MCZ alone (16mg/L for MCZ com-
pared to 64 mg/L for IONPs-CS-MCZ). Conversely, the
nanocarrier displayed sMIC80 values lower thanMCZ for
all bacterial strains except for L. casei, L. zeae and
R. dentocariosa which were the same values for both
treatments. It is noteworthy that treatment of all
Candida and bacterial strains with nanoparticles only
minus MCZ gave no detectable MICs. Taken together,
the results from the preceding section indicate that
IONPs-CS-MCZ nanocarrier was more effective than
Table 2. Values of minimum inhibitory concentration (MIC) of
miconazole (MCZ) and MCZ nanocarrier (IONPs-CS-MCZ) for
planktonic (pMIC) and sessile (sMIC50 and sMIC80) cells of 10
different oral Candida albicans strains and one type strain,
ATCC 10,231. MIC values calculated from two independent
experiments with quadruplicate technical replicates.
MCZ (mg/L) IONPs-CS-MCZ (mg/L)
C. albicans strains pMIC sMIC50 sMIC80 pMIC sMIC50 sMIC80
BC020 4 4 32 4 0.25 4
BC023 4 16 128 4 4 4
BC037 4 0.25 16 4 0.25 0.25
BC038 4 16 32 4 0.25 16
BC039 4 32 32 4 0.25 8
BC117 4 8 32 4 0.25 1
BC136 4 16 32 4 0.25 2
BC044 2 0.25 32 2 0.25 2
BC145 4 8 32 4 0.25 2
BC146 2 8 32 2 0.25 2
ATCC 10,231 4 16 64 4 2 32
Table 3. Values of minimum inhibitory concentration (MIC) of miconazole (MCZ) and MCZ nanocarrier (IONPs-CS-MCZ) for
planktonic (pMIC) and sessile (sMIC50 and sMIC80) cells of the species included in the different studied biofilm models. All MIC
tests were carried out on two separate occasions in quadruplicate wells of a 96-well plate.
pMIC [mg/L] sMIC50 [mg/L] sMIC80 [mg/L]
Biofilm model MCZ IONPs-CS-MCZ MCZ IONPs-CS-MCZ MCZ IONPs-CS-MCZ
C. albicans 3153A C/G/D 4 4 8 <0.5 16 4
S. mitis 12,261 G/D 4 4 16 16 >256 64
S. oralis 11,427 G/D 4 4 4 4 >256 64
S. intermedius 20,573 G/D <1 <1 64 64 256 64
S. mutans 10,449 C 4 4 128 64 256 64
V. dispar 11,831 C/G/D 16 16 32 16 >256 32
A. naeslundii 17,233 C/G/D 8 8 16 64 256 128
F. nucleatum 10,953 C/G 4 4 32 16 32 16
F. nucleatum vincentii 10,507 G 2 2 16 4 32 8
L. casei 20,011 C/D 16 16 >256 256 >256 >256
L. zeae 20,178 D 16 16 >256 64 >256 >256
R. dentocariosa 43,762 D >128 8 32 32 64 64
Note: Capital letters C, G and D represent, respectively, the caries, gingivitis and denture biofilm models.
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MCZ alone against biofilms containing C. albicans and
most bacterial species investigated in this study.
Biofilm characterization
For all three evaluated oral models, significant reductions
in the metabolic activity and total biomass were observed
for all biofilms after exposure to IONPs-CS-MCZ com-
pared to the control group, with values ranging from 28
to 86.6% (Panels A and B in Figures 1, 2 and 3), except
for gingivitis model biomass, which did not significantly
differ from the control group (Figure 1A). However, no
statistical differences were seen in the metabolic activity
or biomass between the MCZ- and nanocarrier- treated
biofilms. SEM analyses highlighted that the control
group showed a robust scaffold with dense network of
interconnected cells. Bacteria were visibly adhered to the
yeast and hyphae ofC. albicans (denoted by white arrows
in Figures 1C, 2C and 3C). Such adhesion between
bacteria and fungi was still visible following treatment
with MCZ only and the nanocarrier containing the drug
(Figure 1D and 1E, 2D and 2E and 3D and 3E).
Interestingly, exposure to the nanocarrier resulted in
a reduction in biofilm coverage with certain areas of
the coverslips now visible in the gingivitis and caries
model (denoted by yellow arrows in Figures 1E and
3E). A similar trend was seen for the MCZ only treat-
ment in the caries model (Figure 3D). However, biofilm
coverage was relatively comparable between the
untreated, MCZ- and nanocarrier-treated samples for
the denture biofilm model with no obvious change in
the biofilm coverage or thickness (Figure 2C and 2E). In
all models less hyphae were present in IONPs-CS-MCZ-
treated biofilms compared to untreated controls, with
Candida visible mostly in the form of yeast cells
(Figures 2E, 3E and 4E).
Quantitative biofilm assessment
Figure 4 shows the effect of the nanocarrier IONPs-CS-
MCZ on the gingivitis biofilm model, compared with
the MCZ treatment alone, and negative control
untreated biofilms. Overall, CFU and CFE quantifica-
tions revealed that the number of all microorganisms
treated with MCZ only and IONPs-CS-MCZ were
reduced in comparison to the control group (Figure 4
and Supplementary Figure 1). In this biofilmmodel, the
effects of MCZ alone and MCZ in the nanosystem were
Figure 1. Results of XTT reduction assay (A), quantification of total biomass (B) and scanning electron microscopy (SEM)
observation (C) for the gingivitis biofilm model untreated (control) and (D) treated with the miconazole (MCZ) only or (E)
nanocarrier containing MCZ at 64 mg/L (IONPs-CS-MCZ) anaerobically for 24 hours. Magnification of the SEM images: 1,000x and
3,500x; Bars: 10 and 5 µm. Significant differences between the groups were calculated by one-way ANOVA with Tukey’s post-
hoc test (* p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.0001). Results shown in A and B representative of a total of 9 values for
each treatment e.g., three technical replicates from three separate experiments. White arrows represent adhesion of bacteria to
yeasts/hyphae. Yellow arrows highlight the visible coverslip due to loss of biofilm biomass by IONPs-CS-MCZ.
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more evident against the bacterial cells and less so
against the Candida cells. The compositional analysis
of the gingivitis biofilm model showed that treatment
with MCZ and with the nanocarrier altered the compo-
sition of the biofilm (Figure 4G, Table 4 and
Supplementary Table 1). The greatest change occurred
for the Streptococcus spp., which was the most predo-
minant consortia in the biofilm from the control group
(representing ~46% of biofilm total cells), second most
dominant in the MCZ-treated group (~32% of the
total), yet only the third most prevalent in the nanosys-
tem-treated group (~15% of the total).
In the denture model, the number of CFUs and
CFEs of all species after treatment with MCZ and the
nanocarrier decreased compared to the control group
(Figure 5 and Supplementary Figure 2), with the
exception of the two Lactobacillus species whose
numbers did not change in the biofilm following
treatment with MCZ only. However, treatment of
the biofilm with the nanocarrier reduced the numbers
of L. casei and L. zeae by 0.5 log and 1.0 log, respec-
tively, compared to the untreated control biofilm
(Supplementary Figure 2E and F). Unlike the pre-
vious biofilm model, the nanosystem reduced the
amount of Candida cells in the denture biofilm, as
seen using both quantitative techniques (Figure 5A
and 5D). The proportion of microorganisms within
the denture biofilm changed following treatment with
MCZ and IONPs-CS-MCZ (Figure 5G, Table 4 and
Supplementary Table 1). Interestingly, the numbers
of Streptococcus spp. and V. dispar (first [~49%]
and second [~26%] most prevalent genus/species in
the untreated biofilms) were clearly reduced and
replaced by A. naeslundii (~60%) and L. zeae
(~18%) as the most prevalent species in the final
composition of the nanosystem-treated biofilms
(Figure 5G). Similarly, for the MCZ only treated
biofilms, Streptococcus spp. and V. dispar proportions
were reduced to ~11% and ~22%, respectively,
replaced with A. naeslundii (~24%) and L. zeae
(~24%) as the most dominant species following
treatment.
Finally, analyzing the caries model biofilm, CFU data
showed that yeast cells were reduced in number when
exposed toMCZ only and the nanocarrier in comparison
to the control group (Figure 6A). However, the same
pattern was not observed for the CFE counting, as
C. albicans cells reductions were comparable (Figure
Figure 2. Results of XTT reduction assay (A), quantification of total biomass (B) and scanning electron microscopy (SEM) observation (C)
for the denture biofilm model untreated (control) and (D) treated with miconazole (MCZ) only or (E) the nanocarrier containing MCZ at
64 mg/L (IONPs-CS-MCZ) anaerobically for 24 hours. Magnification of the SEM images: 1,000x and 3,500x; Bars: 10 and 5 µm. Significant
differences between the groups were calculated by one-way ANOVAwith Tukey’s post-hoc test (* p < 0.05, **p < 0.01, *** p < 0.001, ****
p < 0.0001). Results shown in A and B representative of a total of 9 values for each treatment e.g., three technical replicates from three
separate experiments. White arrows represent adhesion of bacteria to yeasts/hyphae. Yellow arrows highlight the visible coverslip due to
loss of biofilm biomass following treatment with IONPs-CS-MCZ.
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6D).However, for all the bacterial species included in this
model, there were reductions in the CFU and total CFE
counts (Figure 6B, 6C and 6E and Supplementary
Figure 3), with the exception for the CFE of streptococci
following treatmentwithMCZonly (Supplementary 3A),
and for the CFE of L. casei for both treatments
(Supplementary Figure 3E). These results are also
reflected in the percentages of the biofilm composition.
C. albicans and L. casei increased their prevalence in the
total number of cells for MCZ- and nanocarrier-treated
biofilms (Figure 6G, Table 4 and Supplementary Table 1).
Furthermore, the proportion of Streptococcus spp. in the
biofilm treated with IONPs-CS-MCZ was reduced con-
siderably when compared to the control (~1% for treated
compared to ~17% for untreated).
Interestingly, the proportion of C. albicans
increased in the final composition of all biofilm mod-
els in the MCZ- and IONPs-CS-MCZ-treated bio-
films (~0.1% to ~0.2% and ~0.3%, respectively in
the gingivitis model, ~2.3% to ~14.4% and ~6.5%,
respectively in the denture model and ~4.6% to
~10.9% and ~35.4%, respectively in the caries
model). This is suggestive that Candida is generally
more tolerant to MCZ or IONPs-CS-MCZ treatment
in polymicrobial biofilms than most bacterial species,
although proportions of C. albicans were relatively
low in the gingivitis model (~0.1–0.3%). Taken
together, the results from this study suggest that the
nanocarrier system may improve the efficacy of MCZ
in polymicrobial communities, albeit by targeting
specific genus or species within the consortia. Of
note, Streptococcus spp. numbers were reduced by
1.5–2.5 log in all biofilm models following treatment
with IONPs-CS-MCZ.
Discussion
Our improved understanding that microorganisms form
complex polymicrobial communities, and that interking-
dom interactions play an important role within these, has
paved the way to enhance and develop novel methods
and strategies to manage complex biofilms infections
[33,34]. For the development of new antimicrobials, we
must be conscious of what we are attempting to treat.
Therefore, models that accurately recapitulate the in vivo
scenario are likely to yield breakthroughs in potential
therapeutics. Here, we describe three relevant complex
Figure 3. Results of XTT reduction assay (A), quantification of total biomass (B) and scanning electron microscopy (SEM) observation (C)
for the caries biofilm model untreated (control) and (D) treated with miconazole (MCZ) only or (E) the nanocarrier containing MCZ at
64 mg/L (IONPs-CS-MCZ) anaerobically for 24 hours. Magnification of the SEM images: 1,000x and 3,500x; Bars: 10 and 5 µm. Significant
differences between the groups were calculated by one-way ANOVAwith Tukey’s post-hoc test (* p < 0.05, **p < 0.01, *** p < 0.001, ****
p < 0.0001). Results shown in A and B representative of a total of 9 values for each treatment e.g., three technical replicates from three
separate experiments. White arrows represent adhesion of bacteria to yeasts/hyphae. Yellow arrows indicate areas of coverslip now
visible following treatment.
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interkingdom oral biofilm models to test a novel nano-
carrier system that incorporates MCZ with core-shell
compound of IONPs-CS (Figure 7). We report for the
first time the effect of a MCZ nanocarrier against three
different pathogenic biofilm models, first evaluating the
MICs of MCZ alone and IONPs-CS-MCZ for all studied
microorganisms in planktonic form and mono-species
biofilms, before assessing the changes in number of cells,
biofilm ultrastructure and species composition for the
polymicrobial biofilm models following treatment with
the nanocarrier system.
The results of planktonic and sessile MICs of MCZ
and IONPs-CS-MCZ against several C. albicans
strains showed that the planktonic cells were equally
affected by the tested drugs. However, according to
the sMIC80 results, it was possible to obtain higher
antimicrobial effect at lower concentrations of MCZ
against biofilms, by using a nanocarrier. Miconazole
has been used for over 30 years and is prescribed
specifically against oral fungal infections for topical
use [35,36]. Different from other azoles, MCZ has
a dual mechanism of action; besides interfering with
ergosterol synthesis by inhibition of lanosterol
demethylase, it also inhibits fungal catalase and per-
oxidase, therefore increasing intracellular reactive
oxygen species and leading to cell death [37]. As for
CS, literature suggests that the interaction between
the positively charged drug and the negatively
charged bacterial cell membranes results in the leak-
age of intracellular constituents [38,39]. Therefore,
the lower MIC values found for the IONPs-CS-
MCZ could be explained by the synergistic action
between CS and MCZ or that drug-delivery nanosys-
tems are designed to break through physical barriers
to target the cell of interest [21,40]. Additional data
from this study showed that IONPs-CS-MCZ was
able to act effectively against planktonic and sessile
cells of most microbial species used in the three
biofilm models, confirming that it has both antifungal
and antibacterial activity. Indeed, literature data
Figure 4. Results of counting of colony forming units for total Candida (A), total aerobes (B) and total anaerobes (C) in treated
(MCZ only or IONPs-CS-MCZ) biofilms and untreated controls in the gingivitis model. Colony forming equivalents of viable cells
of Candida (D), total bacteria (E) and total microbes (F) are also shown with biofilm percentage composition represented in
panel G. The composition graph y axis has been set to log scale to allow for visualization of all microbial genus/species. Mean
percentage proportions for each microorganism are shown in Table 4. Mean CFE/ml values for each organism are shown in
Supplementary Table 1. Biofilms were treated anaerobically for 24 hours. Untreated biofilms were cultured under the same
conditions minus drug treatment. Results shown representative of a total of 6 values (three technical replicates from two
separate experiments).
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reports the antibacterial potential of topical use con-
centrations of MCZ, specially against Gram-positive
bacteria [16].
Previous work from our group has led to the
development of three different biofilm models used
in this study (gingivitis, denture and dental caries),
taking into consideration early and later colonizers
involved in the development of biofilms associated
with the aforementioned oral diseases [4,27,28,30].
Since C. albicans is a structurally dominant cell of
many polymicrobial biofilm-related diseases, it was
specifically incorporated in all three biofilm models.
In these models, reductions in the number of CFUs
and metabolic activity for all polymicrobial biofilms
were observed following treatment with MCZ, and
generally reduced further following combination of
MCZ with the nanosystem. In addition, total biomass
for denture and dental caries biofilm models were
corroborated by SEM observations, whereby less
dense biofilms were visible in those treated with
IONPs-CS-MCZ nanocarrier. From the data gathered
for pMIC and sMICs of the nanosytem against
C. albicans strains as mono-species, it could be
postulated that the equilibrium of a complex system
such as biofilm can be broken by attacking its main
support system, in this case, the Candida cells.
Tentatively, it could be proposed that bacterial cells
were more exposed to nanocarrier action resulting
from reductions in the number of hyphae. However,
Candida numbers remained relatively stable in the
multi-species biofilm following treatment with MCZ
or IONPs-CS-MCZ, suggestive that the synergistic
interactions between the bacteria and fungi may be
protecting the latter from the antimicrobial activity of
the drug. This has been described elsewhere, whereby
bacteria such as Streptococcus and Staphylococcus spp.
can confer protection to Candida against antimicro-
bials, and vice versa, when grown in mixed culture
[10,41,42].
For all biofilm models, a significant change in the
predominance of the different species after treatment
with the MCZ nanocarrier was observed. In general,
the most prevalent species in all biofilm models were
aerobic and anaerobic-facultative bacteria, such as
Streptococcus spp., Veillonella spp. and Actinomyces
spp. After exposure to MCZ only and IONPs-CS-
Figure 5. Results of counting of colony forming units for total Candida (A), total aerobes (B) and total anaerobes (C) in MCZ- or
nanocarrier-treated and untreated controls in the denture biofilm model. Panels D, E and F show the colony forming equivalents
of viable cells for Candida, total bacteria and total microbes identified using qPCR, respectively. Biofilm percentage composition
represented in panel G with % composition and raw CFE/ml values shown in Table 4 and Supplementary Table 1. The
composition graph y axis has been set to log scale to allow for visualization of all microbial genus/species. Mature biofilms were
treated anaerobically for 24 hours. Untreated biofilms were cultured under the same conditions minus drug treatment. Results
shown representative of a total of 6 values (three technical replicates from two separate experiments).
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MCZ, it becomes noticeable that proportionally the
reduction in the number of most bacterial cells was
much higher than that noted for C. albicans; which
increased in percentage of the final composition in all
models. A limitation of this study was the inability to
distinguish between the numbers of yeast and hyphal
Candida cells using the CFU and CFE counts. SEM
analyses highlighted that fewer hyphae were present
in the nanocarrier system-treated biofilms compared
to controls, which may suggest that the treatment
inhibited the ability of Candida to form and/or main-
tain hyphae. Therefore, the reduction in bacterial
counts may be explained by the role of Candida in
providing structural support for the bacterial com-
munity. The Candida yeast cell form has around
6.6 µm diameter, but its hyphae are much larger in
size [43] and therefore serve as a scaffold for the
smaller bacterial cells to attach [6]. Loss of this sup-
port structure may have resulted in the observed
reductions in bacterial cell numbers.
Interestingly, for all biofilm models, Streptococcus
spp. appeared to be most affected by the MCZ nano-
carrier. This was particularly evident for the dental
caries biofilm model. These results suggest that MCZ-
based formulations may be an interesting method of
treatment for polymicrobial biofilms that contain
recognized microbial synergistic associations. For
example, in the caries biofilm model, S. mutans-
derived α-glucans surrounding the fungal cells could
provide an additional ‘drug capture matrix’ that pre-
vented uptake of antifungals, therefore reducing
Candida cell death [44]. These interactions between
Candida and bacteria are largely reported, especially
Candida-Streptococcus interactions. For example,
C. albicans can promote streptococci proliferation
by providing suitable environmental conditions [8].
Conversely, some Streptococcus spp. such as S. mutans
can produce glucosyltranferases that bind to the fun-
gal surface. In addition, S. mutans generates extracel-
lular polysaccharides (EPS) in the presence of
Figure 6. Results of counting of colony forming units for total Candida (A), total aerobes (B) and total anaerobes (C) in MCZ- or
nanocarrier-treated and untreated controls in the caries biofilm model. Colony forming equivalents of viable Candida and total
bacteria cells are shown in panels D (Candida), E (bacteria) and F (all microbes). Biofilm percentage composition in treated and
untreated controls represented in panel G, shown with Log scaling to depict all microbial genus/species. Percentage composi-
tion and raw CFE/ml for each microorganism is shown in Table 4 and Supplementary Table 1. Biofilms were treated
anaerobically for 24 hours. Untreated biofilms were cultured under the same conditions minus drug treatment. Results
shown representative of a total of 6 values (three technical replicates from two separate experiments).
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sucrose, provide binding site for S. mutans while
allowing C. albicans to adhere and colonize abiotic
surfaces [7,9]. Interestingly, in the caries model the
CFE counts for Candida showed no change following
MCZ- or MCZ-nanocarrier system treatment. It
could be postulated that S. mutans-derived carbohy-
drates is protecting Candida from the MCZ effects.
In general, IONPs-CS-MCZ nanocarrier showed
a great versatility since it was able to reduce the
number of viable cells in all the three pathogenic
biofilm models tested, as well as the ability to pro-
mote changes in biofilm composition. This suggests
that the nanocarrier may have the potential to fight
important oral diseases (gingivitis, caries and denture
stomatitis) associated with polymicrobial interking-
dom biofilms formed by microbial species that estab-
lish beneficial interactions with each other.
Nevertheless, future studies should be conducted to
evaluate the effect of the nanocarrier on microcosm
biofilms, as well as tests that explore the magnetic
properties of the nanoparticles on improving drug
delivery accuracy. These analyses will bring new
knowledge about the antibiofilm effect of the
IONPs-CS-MCZ nanocarrier which may favor the
delivery of MCZ to the target cells, reducing the
drug concentration used. Future studies most also
consider conducting cytotoxicity tests on human
cells if the nanocarrier system is to be considered as
a potential therapeutic for clinical trials.
In summary, IONPs-CS-MCZ nanocarrier affected
the composition of the three evaluated biofilms, caus-
ing high reduction of Streptococcus cells for all
biofilms and enhanced proportion of V. dispar,
A. naeslundii and C. albicans in the gingivitis, denture
and dental caries models, respectively. This alteration
was directly related to the antibiofilm effect of this
compound possibly arising from reductions of
C. albicans numbers and loss of biofilm integrity.
Whether such nanocarrier systems can be used
in vivo remains to be seen; however, it is clear that
such technology has promising potential to circum-
vent the physical barrier presented by polymicrobial
biofilms to enhance drug delivery and efficacy.
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